The FDA published an introductory briefing document and seven substance-specific evaluations before the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting on proposed additions to the 503A Bulks List.
The FDA Published Seven Peptide Evaluations Ahead of PCAC Meeting
As of July 21, 2026, the U.S. Food and Drug Administration (FDA) website has published an introductory briefing document and seven substance-specific evaluations ahead of the July 23–24 Pharmacy Compounding Advisory Committee (PCAC) meeting. The briefing documents recommend against adding the free base and acetate forms of seven peptide-related bulk drug substances to the 503A Bulks List. In Med Spa and aesthetic settings, the evaluations may inform practices reviewing product sourcing, prescribing, and regulatory developments involving compounded peptide substances.
Pre-Meeting FDA Documents Recommend Against Free Base and Acetate Forms of Seven Peptides
The July 2026 Pharmacy Compounding Advisory Committee meeting follows several recent FDA actions involving peptide compounding. Earlier this year, HHS Secretary Robert F. Kennedy Jr. discussed possible changes to peptide regulation. In March 2026, the FDA also finalized the removal of 12 peptide substances from the 503A Category 2 Bulk Drug Substances List.
Ahead of the meeting, the FDA published an introductory briefing document and seven substance-specific evaluations for committee review. The committee is scheduled to consider whether each substance should be added to the 503A Bulks List and provide recommendations for the FDA’s consideration.
The committee’s recommendations are advisory and do not determine the agency’s final decision. Each of the seven peptide-specific briefings includes the FDA’s evaluation of available information, compounding safety considerations, and the agency’s recommendation for the substance under review.
The following peptide-related bulk drug substances are being considered for possible inclusion on the 503A Bulks List:
- BPC-157
- Emideltide
- Epitalon
- KPV
- MOTS-c
- Semax
- TB-500
For each substance, the FDA evaluated four statutory factors, including characterization of the substance, compounding safety considerations, available evidence, and the substance’s history in compounded drug products. As of this reporting, the FDA recommends against adding the free base and acetate forms of each of the seven peptide-related bulk drug substances to the 503A Bulks List.
DISCOVER YOUR MED SPA’S GROWTH POTENTIAL
How much time and revenue could you unlock by outsourcing your GFEs?
Use our GFE Calculator to find out in under 5 minutes. It’s quick, easy, and tailored to your Med Spa.
FDA Briefing Documents
According to the FDA’s published briefing documents and the Pharmacy Compounding Advisory Committee meeting agenda, the July 23–24, 2026 meeting will review recommendations regarding seven peptide-related bulk drug substances proposed for the 503A Bulks List.
503A Compounding Oversight and Compliance Context
Section 503A of the Federal Food, Drug, and Cosmetic Act establishes the federal framework for traditional pharmacy compounding. Bulk drug substances nominated for inclusion on the 503A Bulks List undergo FDA review using statutory criteria before the agency determines whether they may be appropriate for compounding. The Pharmacy Compounding Advisory Committee reviews the FDA’s evaluations and provides advisory recommendations, while the FDA makes the final regulatory determination.
The FDA also publishes guidance and safety information related to compounded drug products, including information on certain bulk drug substances the agency states may present significant safety risks when used in compounding. Federal oversight of compounded medications has also included actions involving GLP-1 drugs, inspections, warning letters, and policy documents addressing pharmacy compounding and related regulatory requirements.
Regulatory actions involving compounded medications may involve both federal agencies and state licensing boards. Recent state-level action includes the California Medical Board GLP-1 compounding case involving allegations related to compounded medications, labeling, and dispensing practices. For operators monitoring peptide-related services, FDA policy and applicable state regulatory requirements may provide additional examples of how compounding-related concerns may be addressed at the state level alongside federal oversight.
Practical Implications for Providers and Med Spa Operators
- Review FDA compounding policies involving peptide-related bulk drug substances and other compounded medications.
- Confirm peptide-related medications and compounded drug products are obtained through lawful suppliers operating under applicable federal and state requirements.
- Verify relationships with compounding pharmacies and medication suppliers to ensure appropriate licensure and regulatory compliance.
- Differentiate between federal oversight of pharmacy compounding and state requirements governing prescribing, delegation, supervision, and scope of practice.
- Track FDA decisions and Pharmacy Compounding Advisory Committee recommendations involving peptide-related bulk drug substances.
What to Watch Next
Following the committee’s review, the FDA will consider the advisory recommendations before determining whether the free base and acetate forms of the seven peptide-related bulk drug substances will be added to the 503A Bulks List. Future FDA actions may provide additional information on the agency’s final decisions for each nominated substance.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “FDA Bldg 31 – Great Room” by The U.S. Food and Drug Administration, via Wikimedia Commons, licensed under Public Domain.
